Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer

被引:37
作者
Cohn, David E. [1 ]
Hall, Nathan C. [2 ]
Povoski, Stephen P. [3 ]
Seamon, Leigh G. [1 ]
Farrar, William B. [3 ]
Martin, Edward W., Jr. [3 ]
机构
[1] Ohio State Univ, Coll Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Dept Radiol, Sect PET,Div Nucl Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med, Div Surg Oncol, Dept Surg, Columbus, OH 43210 USA
关键词
PET; F-18-FDG; cytoreduction; ovarian cancer;
D O I
10.1016/j.ygyno.2008.04.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Diagnostic F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) is an established method for detecting ovarian cancer. However, there is no established method to detect hypermetabolic tumor intraoperatively to evaluate disease extent and assure complete resection. We describe an innovative approach for intraoperative tumor localization and verification of tumor resection utilizing F-18-FDG for perioperative PET/CT imaging and intraoperative gamma probe detection in ovarian cancer. Methods. Three patients with recurrent ovarian cancer in the lymph nodes were evaluated. Diagnostic F-18-FDG PET/CT was performed before surgery to establish the disease location. Preoperatively, F-18-FDG was injected intravenously. Intraoperatively, tumors were localized with a handheld gamma probe. Postoperatively, resected tumors were scanned with a specimen PET/CT to confirm metabolic activity in those specimens. Results. All patients had recurrent epithelial ovarian cancer with groin or retroperitoneal lymph node metastasis diagnosed with PET/CT. In two patients, intraoperative gamma probe detection, specimen PET/CT, and postoperative PET/CT verified complete resection of the clinical and hypermetabolic lesions (in one case, the extent of disease was not fully apparent intraoperatively by gross palpation or inspection). The other patient was demonstrated to have extensive, unresectable disease in the porta hepatis and celiac axis, much of which was recognized only with the intraoperative gamma probe and not with the initial intraoperative survey. Conclusions. Perioperative PET/CT imaging with intraoperative detection using a gamma probe following a single F-18-FDG injection dose is feasible, establishes the location and extent of disease, and confirms a complete cytoreduction for recurrent ovarian cancer. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 25 条
[1]   Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer [J].
Barranger, E ;
Kerrou, K ;
Petegnief, Y ;
David-Montefiore, E ;
Cortez, A ;
Daraï, E .
GYNECOLOGIC ONCOLOGY, 2005, 96 (01) :241-244
[2]   Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes [J].
Bristow, RE ;
Giuntoli, RL ;
Pannu, HK ;
Schulick, RD ;
Fishman, EK ;
Wahl, RL .
GYNECOLOGIC ONCOLOGY, 2005, 99 (02) :294-300
[3]   Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT [J].
Bristow, RE ;
del Carmen, MG ;
Pannu, HK ;
Cohade, C ;
Zahurak, ML ;
Fishman, EK ;
Wahl, RL ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2003, 90 (03) :519-528
[4]  
Desai D, 1999, Clin Positron Imaging, V2, P325, DOI 10.1016/S1095-0397(99)00085-0
[5]  
Desai D C., 2000, Clin Positron Imaging, V3, P189, DOI 10.1016/S1095-0397(00)00052-2
[6]  
EISENKOP SM, 1995, CANCER, V76, P1606, DOI 10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO
[7]  
2-H
[8]   Advances in FDG PET probes in surgical oncology [J].
Essner, R ;
Daghighian, F ;
Giuliano, AE .
CANCER JOURNAL, 2002, 8 (02) :100-108
[9]   The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma [J].
Franc, BL ;
Mari, C ;
Johnson, D ;
Leong, SP .
CLINICAL NUCLEAR MEDICINE, 2005, 30 (12) :787-791
[10]  
GULEC SA, 2006, ANN SURG ONCOL 0724